Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noaf285 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Amy A Smith und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Cleveland Clinic Children's (A.A.S.). Hauptthemen laut MEDLINE: Ependymoma, Brain Neoplasms, Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Children's Oncology Group, Team Ax Foundation.
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
Background
The utility of chemotherapy for childhood ependymoma is uncertain without a prior randomized trial.
Methods
ACNS0831, a multicenter phase 3 randomized study conducted through the Children’s Oncology Group (COG), included patients 1-21 years with newly diagnosed intracranial ependymoma. Patients with complete/near-total resections (GTR/NTR) or complete response (CR) to induction therapy were randomized to radiation (RT) alone or RT followed by chemotherapy (RT-CHEMO). Primary outcomes were event-free survival (EFS) and overall survival (OS). Due to anticipated noncompliance with chemotherapy, an “as treated” analysis was planned. Patients with subtotal resection (STR) were non-randomly assigned to RT-CHEMO. Grade 2 supratentorial tumors with GTR or CR to induction therapy were observed.
Results
Of 449 eligible patients, 325 with GTR/NTR or CR were randomized. Five-year EFS was 63.7% (95% CI: 55.1%-71.1%) for RT only (n = 161) versus 69.2% (60.8%-76.3%) for RT-CHEMO (n = 164) (1-sided log-rank P = .299, HR = 0.866). Five-year OS was 86.9% (79.8%-91.6%) for RT only versus 88.3% (81.8%-92.6%) for RT-CHEMO (1-sided log-rank P-value = .172, HR = 0.757). The “as treated” and “as randomized” analysis results were similar. Sixty-three subjects with STR were assigned to RT-CHEMO; 5-year EFS was 33.6% (22.1%-45.5%) and OS 74.0% (60.5%-83.5%). Supratentorial grade 2 tumors with GTR or CR were observed with a 5-year EFS of 66.9% (49.0%-79.7%) and OS of 100%. Molecular classification was provided for 94% (n = 422) of all subjects.
Conclusions
Primary analysis showed no benefit for maintenance chemotherapy. Further follow-up is important to assess its effect on late relapses. This is the largest cohort of molecularly classified ependymomas treated on a Phase 3 randomized trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Cleveland Clinic Children's (A.A.S.).
- Department of Biostatistics, St Jude Children's Research Hospital.
- Department of Pathology, St Jude Children's Research Hospital.
- Department of Radiology, St Jude Children's Research Hospital.
- Department of Oncology, St Jude Children's Research Hospital.
- Department of Pediatrics, University of Colorado Health Sciences Center.
ORCID-Profile: Amy A Smith, Uri Tabori, Stephen Sands, Sarah Leary, Maryam Fouladi, Amar Gajjar
Förderung
- NCI NIH HHS
- Children's Oncology Group
- Team Ax Foundation
- Curing Kids Cancer Foundation
- Children’s Oncology Group Operations
- Children’s Oncology Group Statistics/Data Center
- Children’s Oncology Group
Zitieren
APA
Smith, A. A., Onar-Thomas, A., Lensing, S., Dalton, J., Bennett, J., Tatevossian, R. G., Bertrand, K., Lindsay, H., Tabori, U., Owens-Pickle, E., Blackburn, P. R., Handler, M. H., Chambwe, N., El Khoury, L., Lau, C., Kunin-Batson, A., Sands, S., Wu, S., Zhou, T., …, & Ellison, D. W. (2026). Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf285
Vancouver
Smith AA, Onar-Thomas A, Lensing S, Dalton J, Bennett J, Tatevossian RG, et al. Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf285
BibTeX
@article{Smith2026,
author = {Smith, Amy A and Onar-Thomas, Arzu and Lensing, Shelly and Dalton, James and Bennett, Jeffrey and Tatevossian, Ruth G and Bertrand, Kelsey and Lindsay, Holly and Tabori, Uri and Owens-Pickle, Emily and Blackburn, Patrick R and Handler, Michael H and Chambwe, Nyasha and El Khoury, Louis and Lau, Ching and Kunin-Batson, Alicia and Sands, Stephen and Wu, Shengjie and Zhou, Tianni and Chang, Andrew and Merchant, Thomas E and Leary, Sarah and Fouladi, Maryam and Gajjar, Amar and Pollack, Ian F and Foreman, Nicholas K and Ellison, David W},
title = {Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noaf285}
}
EUVIMED